◆ NeutralBAYRY
Orion-konsernin puolivuosikatsaus tammi–kesäkuu 2026
GlobeNewswire Inc.·
Orion reported strong H1 2026 results with revenue of €939.3 million (+21.8% YoY) and operating profit of €291.3 million (+59.6% YoY). The company raised its 2026 guidance, expecting revenue of €2,000-2,100 million and operating profit of €650-750 million. Key drivers include growth in Nubeqa royalties, FDA approval for Animal Health product Tessie®, and significant progress in ODM-212 cancer drug development with orphan drug designations.
Read Full Article at GlobeNewswire Inc. →